We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




DiaSorin Enters Indian IVD Market

By LabMedica International staff writers
Posted on 01 Aug 2012
Print article
DiaSorin (Saluggia, Italy) continues its expansion plan in Asia through the establishment of a Joint Venture Company (JV) with local partner Trivitron Healthcare (Chennai, India), an Indian medical technology company focused on manufacturing and distribution, with solutions in the in vitro diagnostics business.

DiaSorin has signed a joint venture (JV) with Trivitron Healthcare to enter India's EUR 400 million IVD market. Financial terms were not available.

In accordance with the JV Agreement, DiaSorin Group and Trivitron Group formed the limited liability company dubbed DiaSorin Trivitron Healthcare Private Ltd., headquarted in Chennai, in which the companies have 51% and 49% share respectively. It will directly operate in the Indian diagnostics market.

Device and diagnostics companies have known for some time that they can make better progress in India, which is the world's second fastest growing IVD market after China, by joining forces with a local partner.

Carlo Rosa, CEO of DiaSorin Group, commented, "The JV agreement with Trivitron is really important for the success of DiaSorin Group in a such relevant market as India, and represents an important pillar of the current and future expansion strategy of DiaSorin Group in Asia Pacific. [….] By combining the quality of DiaSorin systems and tests to Trivitron’s extensive knowledge of the Indian market, I’m confident that India will represent another important leg of revenues for us in the Asian region."

DiaSorin is active internationally in the market for in vitro diagnostics and immunodiagnostics. It develops, on an ongoing basis, a vast and innovative line of products that are used in analysis laboratories at universities, hospitals, and private testing facilities.

Trivitron is a global medical technology company of Indian origin focused on manufacturing, innovation, and distribution. The key focus segments include cardiology & implantable devices, imaging sciences (IVD), diagnostics, critical life support solutions (CLSS), and ophthalmology and dental technologies.

Related Links:

DiaSorin
Trivitron Healthcare


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.